UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 12b-25

 

Commission File Number 000-33167

 

NOTIFICATION OF LATE FILING

 

(Check One): [X] Form 10-K [  ] Form 11-K [  ] Form 20-F [  ] Form 10-Q [  ] Form N-SAR

 

For Period Ended: December 31, 2018

 

[  ] Transition Report on Form 10-K   [  ] Transition Report on Form 10-Q
     
[  ] Transition Report on Form 20-F   [  ] Transition Report on Form N-SAR
     
[  ] Transition Report on Form 11-K    

 

For Transition Period Ended: ____________________________________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:____________________________________________________________

 

PART I

REGISTRANT INFORMATION

 

Full name of registrant : KIWA BIO-TECH PRODUCTS GROUP CORPORATION

 

Address of principal executive office (Street and number): 3200 Guasti Road, Suite 100, Ontario, California 91761

 

 

 

 
     

 

PART II

RULE 12-b 25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

[  ] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

[  ] (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III

NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

 

The Registrant is unable to file its Form 10-K within the prescribed time period without unreasonable effort or expense. The Registrant anticipates that it will file its Form 10-K within the grace period provided by Exchange Act Rule 12b-25.

 

PART IV

OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification: Yvonne Wang, Chief Executive Officer, Tel. (626) 715-5855.

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 

[X] Yes [  ] No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

[  ] Yes [X] No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
     

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION

(Name of Registrant as Specified in Charter)

 

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

  KIWA BIO-TECH PRODUCTS GROUP CORPORATION
   
  By: /s/ Yvonne Wang
    Yvonne Wang
    Chief Executive Officer

 

Date: April 1, 2019

 

 
     

 

Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kiwa Bio Tech Products (CE) Charts.
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kiwa Bio Tech Products (CE) Charts.